<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Statins for primary prevention of venous thromboembolism - Li, L - 2014 | Cochrane Library</title> <meta content="Statins for primary prevention of venous thromboembolism - Li, L - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008203.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Statins for primary prevention of venous thromboembolism - Li, L - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008203.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008203.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Statins for primary prevention of venous thromboembolism" name="citation_title"/> <meta content="Lun Li" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="Peizhen Zhang" name="citation_author"/> <meta content="Hospital of Lanzhou City" name="citation_author_institution"/> <meta content="Jin Hui Tian" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="tianjh@lzu.edu.cn" name="citation_author_email"/> <meta content="KeHu Yang" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD008203.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/12/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008203.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008203.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008203.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Fluorobenzenes [adverse effects, *therapeutic use]; Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; Myocardial Infarction [prevention &amp; control]; Pyrimidines [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke [prevention &amp; control]; Sulfonamides [adverse effects, *therapeutic use]; Venous Thromboembolism [*prevention &amp; control]; Venous Thrombosis [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008203.pub3&amp;doi=10.1002/14651858.CD008203.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008203\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008203\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008203.pub3",title:"Statins for primary prevention of venous thromboembolism",firstPublishedDate:"Dec 18, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008203.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008203.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008203.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008203.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008203.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008203.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008203.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008203.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008203.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008203.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2358 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008203.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/appendices#CD008203-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/table_n/CD008203StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/table_n/CD008203StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Statins for primary prevention of venous thromboembolism</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#CD008203-cr-0002">Lun Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#CD008203-cr-0003">Peizhen Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#CD008203-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jin Hui Tian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information#CD008203-cr-0005">KeHu Yang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information/en#CD008203-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 December 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008203.pub3">https://doi.org/10.1002/14651858.CD008203.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008203-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008203-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008203-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008203-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008203-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008203-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008203-abs-0001" lang="en"> <section id="CD008203-sec-0001"> <h3 class="title" id="CD008203-sec-0001">Background</h3> <p>Venous thromboembolism (VTE) is common in clinical practice. The efficacy of statins in the primary prevention of VTE remains unproven. This is an update of the review first published in 2011. </p> </section> <section id="CD008203-sec-0002"> <h3 class="title" id="CD008203-sec-0002">Objectives</h3> <p>To assess the efficacy of statins in the primary prevention of VTE.</p> </section> <section id="CD008203-sec-0003"> <h3 class="title" id="CD008203-sec-0003">Search methods</h3> <p>For this update the Cochrane Peripheral Vascular Diseases (PVD) Group Trials Search Co‐ordinator searched the Specialised Register (last searched February 2014) and CENTRAL (2014, Issue 1). </p> </section> <section id="CD008203-sec-0004"> <h3 class="title" id="CD008203-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that assessed statins in the primary prevention of VTE were considered. The outcomes we evaluated were the rates of VTE, cardiovascular and cerebrovascular events, death and adverse events. Two authors (L Li, JH Tian) independently selected RCTs against the inclusion criteria. Disagreements were resolved by discussion with a third author (KH Yang). </p> </section> <section id="CD008203-sec-0005"> <h3 class="title" id="CD008203-sec-0005">Data collection and analysis</h3> <p>Data extraction was independently carried out by two authors (L Li, JH Tian). Disagreements were resolved by discussion with a third author (PZ Zhang). Two authors (L Li, JH Tian) independently assessed the risk of bias according to a standard quality checklist provided by the PVD Group. </p> </section> <section id="CD008203-sec-0006"> <h3 class="title" id="CD008203-sec-0006">Main results</h3> <p>For this update we included one RCT with 17,802 participants that assessed rosuvastatin compared with placebo for the prevention of VTE. The quality of the evidence was moderate because of imprecision, as the required sample size for the outcomes of this review was not achieved. Analysis showed that when compared with placebo rosuvastatin reduced the incidence of VTE (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.37 to 0.86) and deep vein thrombosis (DVT) (OR 0.45, 95% CI 0.25 to 0.79), the risk of any (fatal and non‐fatal) myocardial infarction (MI) (OR 0.45, 95% CI 0.30 to 0.69), and any (fatal and non‐fatal) stroke (OR 0.51, 95% CI 0.34 to 0.78). There was no difference in the incidence of pulmonary embolism (PE) (OR 0.77, 95% CI 0.41 to 1.46), fatal MI (OR 1.50, 95% CI 0.53 to 4.22), fatal stroke (OR 0.30, 95% CI 0.08 to 1.09) or death after VTE (OR 0.50, 95% CI 0.20 to 1.24). The incidence of any serious adverse events was no different between the rosuvastatin and placebo groups (OR 1.07, 95% CI 0.95 to 1.20). </p> </section> <section id="CD008203-sec-0007"> <h3 class="title" id="CD008203-sec-0007">Authors' conclusions</h3> <p>Available evidence showed that rosuvastatin was associated with a reduced incidence of VTE, but the evidence was limited to a single RCT and any firm conclusions and suggestions could be not drawn. Randomised controlled trials of statins (including rosuvastatin) are needed to evaluate their efficacy in the prevention of VTE. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008203-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008203-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008203-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008203-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008203-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008203-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008203-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008203-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008203-abs-0004" lang="en"> <h3>Statins for preventing blood clot formation within veins</h3> <p>Background</p> <p>Venous thrombosis or thromboembolism (VTE) is a condition in which a blood clot (thrombus) forms in a vein and causes a blockage. The blockage most commonly occurs in the 'deep veins' of the lower legs, thighs or pelvis and is called deep vein thrombosis (DVT). If part of or the entire clot breaks away and is carried through the blood (venous) system it is called an embolism. Should the clot reach the lungs, it is known as a pulmonary embolism (PE) and is life threatening. VTE affects about 3,705,000 people worldwide annually and is one of the most preventable causes of hospital deaths. Statins are well known cholesterol‐lowering drugs that are used in heart disease. They have other protective effects including anti‐clotting properties and may be effective in the prevention of VTE. The objective of this review was to assess the efficacy of statins in the primary prevention of VTE. </p> <p>Key results</p> <p>Our review included one published randomised controlled trial, involving 17,802 participants, which reported outcomes of VTE. This trial investigated rosuvastatin compared with placebo for the primary prevention of VTE. Analysis showed that, compared with placebo, rosuvastatin reduced the incidence of VTE and DVT, the risk of any (fatal and non‐fatal) myocardial infarction, and any (fatal and non‐fatal) stroke. There were no differences between rosuvastatin and placebo in the incidence of pulmonary embolism, fatal myocardial infarction, fatal stroke, and death after VTE. The incidence of any serious adverse events was not different between rosuvastatin and placebo. No firm conclusions or suggestions could be made from these findings. More randomised controlled trials of statins (including rosuvastatin) are needed to evaluate the efficacy of statins in the prevention of VTE. </p> <p>Quality of the evidence</p> <p>The quality of the evidence was moderate because of imprecision, as the required sample size for the outcomes of this review was not achieved. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008203-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008203-sec-0094"></div> <h3 class="title" id="CD008203-sec-0095">Implications for practice</h3> <section id="CD008203-sec-0095"> <p>Available evidence showed that rosuvastatin was associated with a reduced incidence of VTE, but the evidence was limited to a single RCT and any firm conclusions and suggestions could not be drawn. Randomised controlled trials of statins (including rosuvastatin) are needed to evaluate their efficacy in the prevention of VTE. </p> </section> <h3 class="title" id="CD008203-sec-0096">Implications for research</h3> <section id="CD008203-sec-0096"> <p>Further double‐blind randomised controlled trials (RCTs) of statins (including rosuvastatin) for preventing VTE are required to provide conclusive evidence. Trials evaluating these outcomes as primary endpoints should be large and of reasonable duration, to confirm the conclusions from the <a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>. This systematic review only evaluated the efficacy of rosuvastatin in the prevention of VTE; other statins have not been tested in RCTs. Therefore, future trials should attempt to determine the efficacy of other statins for preventing VTE, whether this is a class effect seen with all statins, and whether the effect is dose‐dependent. In addition, future prospective studies that carefully investigate the underlying mechanisms of the effects of statins in the prevention of VTE are strongly encouraged. Our review has a different conclusion from that by <a href="./references#CD008203-bbs2-0064" title="RahimiK , BhalaN , KamphuisenP , EmbersonJ , Biere‐RafiS , KraneV , et al. Effect of statins on venous thromboembolic events: a meta‐analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine2012;9(9):e1001310. ">Rahimi 2012</a>, suggesting that unpublished data from published RCTs may result in a different effect size. Therefore, we recommend that any RCTs investigating statins in the primary prevention of any disease should report VTE in their publications. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008203-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008203-sec-0029"></div> <div class="table" id="CD008203-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Statin versus placebo for primary prevention of venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Statin versus placebo for primary prevention of venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (&lt; 130 mg/dL)<br/> <b>Settings:</b> 1315 sites in 26 countries on 4 continents, including North and South America, Europe, and Africa<br/> <b>Intervention:</b> rosuvastatin 20 mg daily versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Statin versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cases of VTE</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.57</b> <br/> (0.37 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./full#CD008203-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary embolism</b> <br/> Follow‐up: mean 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Deep vein thrombosis</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any MI</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.45</b> <br/> (0.3 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (2 to 5) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any stroke</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.51</b> <br/> (0.34 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.8</b> <br/> (0.66 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (18 to 27) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (19 to 27) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any serious adverse event</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.07</b> <br/> (0.95 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (63 to 78) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (63 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Total sample size is lower than the calculated optimal information size (OIS). Therefore the evidence was downgraded based on imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD008203-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial sequential analysis results for the incidence of VTE." data-id="CD008203-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis results for the incidence of VTE.</p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008203-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008203-sec-0030"></div> <section id="CD008203-sec-0031"> <h3 class="title" id="CD008203-sec-0031">Description of the condition</h3> <p>Venous thromboembolism (VTE) is a clinical entity which has two different manifestations, deep venous thrombosis and pulmonary embolism. Venous thrombosis is a condition in which a blood clot (thrombus) forms in an intact vein as red blood cells, fibrin and, to a lesser extent, platelets and leucocytes (white blood cells) form a mass. Blood flow through the affected vein is limited by the clot, causing swelling and pain. Venous thrombosis most commonly occurs in the 'deep veins' in the lower legs, thighs, or pelvis, so it is usually called deep vein thrombosis (DVT). An embolism is created if a part or all of the blood clot breaks off from the site where it is created and travels through the venous system. If the clot lodges in the lungs a very serious condition arises, pulmonary embolism (PE). </p> <p>The crude annual incidence per 1000 population is 0.83 for VTE, 0.52 for DVT, and 0.31 for PE. The annual incidence per 1000 population after age adjustment to the World Health Organization World Standard Population is 0.57 for VTE, 0.35 for DVT, and 0.21 for PE. If the crude annual incidence of VTE is externally valid, then VTE affects about 17,000 Australians and 3,705,000 people all over the world annually (calculated as 65,000 million all over) (<a href="./references#CD008203-bbs2-0060" title="HoWK , HankeyGJ , EikelboomJW . The incidence of venous thromboembolism: a prospective, community‐based study in Perth, Western Australia. Medical Journal of Australia2008;189(3):144‐7. ">Ho 2008</a>; <a href="./references#CD008203-bbs2-0065" title="RajuNC , HirshJ , EikelboomJW . Duration of anticoagulant therapy for venous thromboembolism. Medical Journal of Australia2009;190(12):659‐60. ">Raju 2009</a>). Retrospective studies reported mortality rates following VTE of 5% to 23% (<a href="./references#CD008203-bbs2-0053" title="GoldhaberSZ . Pulmonary embolism. Lancet2004;363(9417):1295‐305. ">Goldhaber 2004</a>), although in symptomatic patients with adequate anticoagulation mortality was 1% to 2% (<a href="./references#CD008203-bbs2-0051" title="DouketisJD , KearonC , BatesS , DukuEK , GinsbergJS . Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA1998;279(6):458‐62. ">Douketis 1998</a>). It was estimated that more than 900,000 Americans develop DVT each year, and 500,000 of these develop PE with 30% of PEs being fatal (<a href="./references#CD008203-bbs2-0058" title="HeitJA , CohenAT , AndersonFA , on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non‐fatal and fatal venous thromboembolism (VTE) events in the US. Blood ASH Annual Meeting2005;106:Abstract 910. ">Heit 2005</a>). About two‐thirds of all VTE events were related to hospitalisation. Heit et al reported that VTE is the third most common cause of hospital‐related deaths in the United States and the most common preventable cause of hospital deaths (<a href="./references#CD008203-bbs2-0057" title="HeitJA , O'FallonWM , PettersonTM , LohseCM , SilversteinMD , MohrDN , et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population‐based study. Archives of Internal Medicine2002;162(11):1245‐8. ">Heit 2002</a>). </p> <p>Thrombosis prophylaxis can be achieved by physical or pharmacological means. The decision on which prophylaxis is used depends on patient risk factors, the availability of recommended medication, and the clinical judgment of the treating doctor (<a href="./references#CD008203-bbs2-0048" title="ChapmanNH , BrightonT , HarrisMF , CaplanGA , BraithwaiteJ , ChongBH . Venous thromboembolism ‐ management in general practice. Australian Family Physician2009;38(1‐2):36‐40. ">Chapman 2009</a>). The most effective anticoagulants (recommended for prophylaxis in the highest risk patients) are the low molecular weight heparins and fondaparinux (<a href="./references#CD008203-bbs2-0044" title="AlpertJS , ThygesenK , AntmanE , BassandJP . Myocardial infarction redefined ‐ a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology2001;37(3):973. ">Alpert 2001</a>; <a href="./references#CD008203-bbs2-0050" title="DiuguidDL . Choosing a parenteral anticoagulant agent. New England Journal of Medicine2001;345(18):1340‐2. ">Diuguid 2001</a>). Mechanical prophylaxis (that is intermittent pneumatic compression stockings or graduated compression stockings) is recommended for patients with a higher than normal risk of bleeding or as an adjunct to more efficacious pharmacological prophylaxis (<a href="./references#CD008203-bbs2-0048" title="ChapmanNH , BrightonT , HarrisMF , CaplanGA , BraithwaiteJ , ChongBH . Venous thromboembolism ‐ management in general practice. Australian Family Physician2009;38(1‐2):36‐40. ">Chapman 2009</a>; <a href="./references#CD008203-bbs2-0050" title="DiuguidDL . Choosing a parenteral anticoagulant agent. New England Journal of Medicine2001;345(18):1340‐2. ">Diuguid 2001</a>). </p> </section> <section id="CD008203-sec-0032"> <h3 class="title" id="CD008203-sec-0032">Description of the intervention</h3> <p>Statins are 3‐hydroxy‐3‐methylglutaryl (HMG)‐coenzyme A (CoA) reductase inhibitors and they are the most powerful cholesterol‐lowering drugs available. They have also been shown to exhibit several vascular protective effects, with antithrombotic properties (<a href="./references#CD008203-bbs2-0072" title="UndasA , Brummel‐ZiedinsKE , MannKG . Statins and blood coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology2005;25(2):287‐94. ">Undas 2005</a>). As a result, the benefits of statins might accrue not only from their effects on lipid levels but also through their influence on thrombosis and inflammation (<a href="./references#CD008203-bbs2-0043" title="AlbertMA , DanielsonE , RifaiN , Ridker PM. PRINCE Investigators. Effect of statin therapy on C‐reactive protein levels: the pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA2001;286(1):64‐70. ">Albert 2001</a>; <a href="./references#CD008203-bbs2-0061" title="KabaNK , FrancisCW , MossAJ , ZarebaW , OakesD , KnoxKL , et al. Effects of lipids and lipid‐lowering therapy on hemostatic factors in patients with myocardial infarction. Journal of Thrombosis and Haemostasis2004;2(5):718‐25. ">Kaba 2004</a>; <a href="./references#CD008203-bbs2-0072" title="UndasA , Brummel‐ZiedinsKE , MannKG . Statins and blood coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology2005;25(2):287‐94. ">Undas 2005</a>). </p> <p>The Heart and Estrogen/Progestin Replacement Study (HERS), a randomised trial of postmenopausal hormone therapy in American women with cardiovascular disease, first observed a lower risk of VTE in women using statins (<a href="./references#CD008203-bbs2-0054" title="GradyD , WengerNK , HerringtonD , KhanS , FurbergC , HunninghakeD , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine2000;132(9):689‐96. ">Grady 2000</a>). In this trial of 2763 women there were nearly 1000 women using statins and the relative risk (RR) of VTE was 0.5. In a study of administrative data, Ray reported that statins users in Ontario had a 22% lower risk of VTE than those prescribed thyroid replacement therapy (<a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>). An analysis by Yang of the General Practice Research Database (GPRD) in the UK was not able to detect an association between statins use, or other lipid‐lowering drug use, and the risk of unprovoked VTE, but the study was limited by the analysis of a small number of cases (<a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a>). Huerta also examined GPRD data using a longer time period and assessing over 6550 cases, and reported a 15% lower risk of VTE with the use of statins although this was not statistically significant (odds ratio (OR) 0.85) (<a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a>). In a study by <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a> of 4538 patients who had previously experienced a single episode of DVT or PE and 5914 control patients, 3.3% of participants using statins experienced a VTE as compared with 5.7% of controls, which yielded a 59% lower risk of VTE with statins use. This association was not seen with other lipid‐lowering medications, which were not associated with a lower, or higher, risk of VTE. Two prospective observational studies showed that substantial and significant reductions in the risk of VTE were associated with the use of statins, a 50% reduction in the risk among statin users in the HERS (<a href="./references#CD008203-bbs2-0054" title="GradyD , WengerNK , HerringtonD , KhanS , FurbergC , HunninghakeD , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine2000;132(9):689‐96. ">Grady 2000</a>) and a 22% reduction among statin users in Ontario, Canada as calculated on the basis of administrative claims data (<a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>). Four case‐control studies also showed reductions in the risk of venous thrombosis, ranging from 26% to 58%, associated with the use of statins (<a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a>; <a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a>; <a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a>; <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a>; <a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a>) (<a href="#CD008203-tbl-0002">Table 1</a>). </p> <div class="table" id="CD008203-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published studies reporting the frequency of venous thromboembolism (VTE) in statin users and nonusers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Result</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (secondary outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8901/8901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosuvastatin 20 mg daily versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.57 (95% CI 0.37 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4538/5914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55 (95% CI 0.46 to 0.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5824/58240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (95% CI 0.63 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129,288/600,241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR no statin versus statin 1.18 (95% CI 1.06 to 1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377/377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.42 (95% CI 0.23 to 0.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677/677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53 (95% CI 0.37 to 0.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised comparison (part of HERS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1712/1051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.40 (95% CI 0.18 to 0.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,993/61,100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR current/recent statin use 0.8 (95% CI 0.3 to 2.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,993/47,869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.78 (95% CI 0.69 to 0.87)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6,550/10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.70 (95% CI 0.50 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465/1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simvastatin, pravastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simvastatin OR 0.51 (95% CI 0.29 to 0.91)</p> <p>Pravastatin OR 1.85 (95% CI 0.65 to 5.26)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> HERS: Heart and Estrogen/Progestin Replacement Study (HERS)<br/> HR: hazard ratio<br/> IRR: incidence rate ratio<br/> OR: odds ratio </p> </div> </div> <p>However, some people think that statins cannot be recommended for use in either the prevention or the treatment of VTE, and that research studies should attempt to quantify the risk reduction for VTE with statin use (<a href="./references#CD008203-bbs2-0066" title="RayJG , RosendaalFR . The role of dyslipidemia and statins in venous thromboembolism. Current Controlled Trials in Cardiovascular Medicine2001;2(4):165‐70. ">Ray 2001b</a>). We intended to clarify the efficacy and safety of statins in this review. </p> </section> <section id="CD008203-sec-0033"> <h3 class="title" id="CD008203-sec-0033">How the intervention might work</h3> <p>Plausible biological links can be found between statin therapy and reduction of thrombotic risk, mainly targeting the immune system, blood coagulation, endothelium, lipid metabolism and inflammation (<a href="./references#CD008203-bbs2-0062" title="LippiG , FavaloroEJ , Sanchis‐GomarF . Venous thrombosis associated with HMG‐CoA reductase inhibitors. Seminars in Thrombosis and Hemostasis2013;39(5):515‐32. ">Lippi 2013</a>). Statins can exhibit antithrombotic properties that are not associated with changes in lipid profile. Increasing evidence indicates that statins modulate the blood coagulation cascade at multiple levels, leading to reduced thrombogenicity (<a href="./references#CD008203-bbs2-0072" title="UndasA , Brummel‐ZiedinsKE , MannKG . Statins and blood coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology2005;25(2):287‐94. ">Undas 2005</a>). Statins inhibit platelet aggregation and maintain a favourable balance between prothrombotic and fibrinolytic mechanisms (<a href="./references#CD008203-bbs2-0067" title="RayJG . Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Current Opinion in Pulmonary Medicine2003;9(5):378‐84. ">Ray 2003b</a>). Differences between individual statin medications may be due to differences in metabolism (<a href="./references#CD008203-bbs2-0049" title="CorsiniA , BellostaS , BaettaR , FumagalliR , PaolettiR , BerniniF . New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics1999;84(3):413‐28. ">Corsini 1999</a>). For example, simvastatin impairs the activation of prothrombin, factor V (FV) and FXIII, and enhances FVa inactivation by activated protein C (<a href="./references#CD008203-bbs2-0071" title="UndasA , BrummelKE , MusialJ , MannKG , SzczeklikA . Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va initiation. Circulation2001;103(18):2248‐53. ">Undas 2001</a>), which may lead to a reduced risk of venous thrombosis. A recent systematic review showed that statin therapy reduces interleukin 6 (IL‐6) induced expression of C‐reactive protein (CRP) and monocyte chemoattractant protein‐1 (MCP‐1), which has been linked to vein wall fibrosis, promoting post‐thrombotic syndrome (PTS) and recurrent DVT in patients (<a href="./references#CD008203-bbs2-0068" title="RodriguezAL , WojcikBM , WrobleskiSK , MyersDD , WakefieldTW , DiazJA . Statins, inflammation and deep vein thrombosis: A systematic review. Journal of Thrombosis and Thrombolysis2012;33(4):371‐82. ">Rodriguez 2012</a>). Meanwhile, this review suggests that the anti‐thrombotic effects are likely to be exhibited through the anti‐inflammatory properties of statins (<a href="./references#CD008203-bbs2-0068" title="RodriguezAL , WojcikBM , WrobleskiSK , MyersDD , WakefieldTW , DiazJA . Statins, inflammation and deep vein thrombosis: A systematic review. Journal of Thrombosis and Thrombolysis2012;33(4):371‐82. ">Rodriguez 2012</a>). </p> </section> <section id="CD008203-sec-0034"> <h3 class="title" id="CD008203-sec-0034">Why it is important to do this review</h3> <p>The optimal drug in the primary prevention of VTE is one that is efficacious, associated with minimal bleeding risk, and easy to administer. Statins fulfil the latter two criteria, but their efficacy and side effects remain unproven (<a href="./references#CD008203-bbs2-0067" title="RayJG . Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Current Opinion in Pulmonary Medicine2003;9(5):378‐84. ">Ray 2003b</a>). In this review we wanted to assess their efficacy and safety by evaluating randomised controlled trials (RCTs) using statins for the primary prevention of VTE. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008203-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008203-sec-0035"></div> <p>To assess the efficacy of statins in the primary prevention of venous thromboembolism (VTE). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008203-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008203-sec-0036"></div> <section id="CD008203-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008203-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) were considered, without language and publication status restrictions. </p> <p>In this review, only primary prevention trials were included. We used the primary prevention definition provided in the US Preventive Services Task Force Guide to Clinical Preventive Services (USPSTF): to provide primary prevention measures to individuals to prevent the onset of a targeted condition. Primary prevention measures include activities that help avoid a given healthcare problem. </p> <p>We excluded studies if they did not assess the primary outcome of this review, the rate of VTE (DVT and PE), as an outcome in the study. The primary outcome of the review could be assessed as either a primary, secondary or exploratory outcome of the study. </p> </section> <section id="CD008203-sec-0039"> <h4 class="title">Types of participants</h4> <p>Participants were healthy people, patients with diseases other than VTE, or people with risk factors (see <a href="./appendices#CD008203-sec-0100">Appendix 1</a>). </p> </section> <section id="CD008203-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included all types of statin treatment as compared to all types of control interventions, including placebo. </p> </section> <section id="CD008203-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD008203-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008203-list-0001"> <li> <p>The rate of VTE (DVT and PE)</p> </li> </ul> </p> <p>VTE is detected by imaging using venous ultrasonography or venography for confirmation of DVT, and angiography, computed tomography (CT) or a ventilation and perfusion scan (V/Q) for confirmation of PE; or any other recognised confirmatory tests for either DVT or PE. VTE was also divided into unprovoked and provoked venous thrombosis. Unprovoked venous thrombosis was defined as occurring in the absence of known malignancy (diagnosed either before or up to three months after the venous thrombosis), trauma, hospitalisation or surgery within the three months before the event. Provoked venous thrombosis included events that occurred in patients with cancer or during, or shortly after, trauma, hospitalisation or surgery. </p> </section> <section id="CD008203-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008203-list-0002"> <li> <p>The rate of cardiovascular and cerebrovascular events (myocardial infarction (MI), stroke, arterial revascularisation, etc.) </p> </li> <li> <p>The rate of death (all deaths, death after VTE)</p> </li> </ul> <ul id="CD008203-list-0003"> <li> <p>Adverse events:</p> </li> </ul> <ul class="plain" id="CD008203-list-0004"> <li> <ol id="CD008203-list-0005"> <li> <p>adverse events (myopathy, tendon manifestations, etc.);</p> </li> <li> <p>serious adverse events (SAEs).</p> </li> </ol> </li> </ul> </p> <p>SAEs were any adverse events that resulted in any of the following outcomes: death, a life threatening adverse event, inpatient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Important medical events that may not result in death, be life threatening, or require hospitalisation may be considered as serious. </p> </section> </section> </section> <section id="CD008203-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no language or publication status restrictions.</p> <section id="CD008203-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator (TSC) searched the Specialised Register (last searched February 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 1), part of <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). See <a href="./appendices#CD008203-sec-0101">Appendix 2</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Peripheral Vascular Diseases Group module in <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). </p> </section> <section id="CD008203-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched the reference lists of retrieved articles and other related literature reviews. </p> </section> </section> <section id="CD008203-sec-0047"> <h3 class="title" id="CD008203-sec-0047">Data collection and analysis</h3> <section id="CD008203-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We used the search strategies described to obtain titles and abstracts of studies that were potentially relevant to the review. Two authors (L Li, JH Tian) independently selected RCTs of statins in the prevention of VTE by screening titles and abstracts against the predetermined eligibility criteria to discard studies that were not applicable. </p> <p>If we could not decide whether the articles satisfied the inclusion criteria from the abstracts, the full texts of the trials were obtained. If there were two or more publications relating to one trial, only the publication with the most complete data or the pooled data from all the publications was included. Disagreements were resolved by discussion with a third author (KH Yang). </p> </section> <section id="CD008203-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was independently carried out by the same two authors (L Li, JH Tian) and the results were checked for accuracy by a third author (PZ Zhang). Disagreements were resolved by discussion. A paper data extraction form provided by the Peripheral Vascular Diseases (PVD) Group was used to record the following characteristics: </p> <p> <ul id="CD008203-list-0006"> <li> <p>title;</p> </li> <li> <p>authors;</p> </li> <li> <p>publication status (if published, which journal, year of publication, the volume, the issue and the pages; if not published, year in which study was conducted and other relevant details); </p> </li> <li> <p>study design;</p> </li> <li> <p>blinding;</p> </li> <li> <p>method of randomisation;</p> </li> <li> <p>method of concealment of allocation;</p> </li> <li> <p>exclusions post‐randomisation;</p> </li> <li> <p>losses to follow‐up;</p> </li> <li> <p>intention‐to‐treat analysis;</p> </li> <li> <p>country;</p> </li> <li> <p>setting or location of trial;</p> </li> <li> <p>type of participants;</p> </li> <li> <p>risk factors of participants;</p> </li> <li> <p>number of participants;</p> </li> <li> <p>number of participants allocated to each type of intervention;</p> </li> <li> <p>stated inclusion and exclusion criteria;</p> </li> <li> <p>age of participants;</p> </li> <li> <p>sex of participants;</p> </li> <li> <p>doses and routes of administration;</p> </li> <li> <p>duration of the follow‐up;</p> </li> <li> <p>type of VTE;</p> </li> <li> <p>primary and secondary outcomes;</p> </li> <li> <p>references to relevant studies.</p> </li> </ul> </p> </section> <section id="CD008203-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>To avoid bias, we assessed the methodological quality of each trial according to a standard quality checklist provided by the PVD Group. Two authors (L Li, JH Tian) independently assessed the risk of bias of each trial as described below, recorded the information in a table, and provided a narrative description in the text. If there was insufficient information about the study methods, we contacted the authors for further information. If the trial authors did not respond within four or more weeks, we assessed the risk of bias from the available information. Disagreements were resolved by consensus. The following items were assessed as 'low risk' (low risk of bias), 'unclear risk' (uncertain risk of bias), or 'high risk' (high risk of bias). </p> <section id="CD008203-sec-0051"> <h5 class="title">A. The selection bias was evaluated based on the randomisation procedure and allocation concealment </h5> <section id="CD008203-sec-0052"> <h6 class="title">1) Randomisation method</h6> <p>Low risk (low risk of bias): the method allowed participants of studies to have the same chance of receiving each intervention and the investigators described a random component in the sequence generation process, such as referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots. </p> <p>High risk (high risk of bias): the investigators described a non‐random component in the sequence generation process. Usually the description involved some systematic, non‐random approach, such as by odd or even date of birth, some rule based on date (or day) of admission, hospital or clinic record number. Other non‐random approaches are used much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgment or some method of non‐random categorisation of participants, such as allocation by the judgment of the clinician, preference of the participant, the results of a laboratory test or a series of tests, or availability of the intervention. If an open random allocation schedule (for example a list of random numbers) was used or assignment envelopes were used without appropriate safeguards (for example if envelopes were unsealed or non‐opaque, or not sequentially numbered), or any other explicitly unconcealed procedure, we classified the randomisation method as at 'high risk of bias'. </p> <p>Unclear risk: insufficient information was available about the sequence generation process to permit judgment of 'low risk' or 'high risk', for example insufficient information about the randomisation procedure, such as randomisation stated but no information given on the method used. </p> </section> <section id="CD008203-sec-0053"> <h6 class="title">2) Allocation concealment</h6> <p>Low risk (low risk of bias): if the randomisation method that was described would not allow investigators or participants to know or influence the intervention group before eligible participants entered into the study (for example central allocation, including telephone, web‐based and pharmacy‐controlled randomisation; sequentially‐numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes). </p> <p>High risk (high risk of bias): if an open random allocation schedule (for example a list of random numbers) was used, assignment envelopes were used without appropriate safeguards (for example if envelopes were unsealed or non‐opaque, or not sequentially numbered), by alternation or rotation, date of birth or case record number, or any other explicitly unconcealed procedure. </p> <p>Unclear risk: insufficient information about allocation concealment, such as allocation concealment stated but no information available on the method used, or the authors did not report on allocation. </p> <p>The randomisation procedure and allocation schedule are usually impossible to achieve low risk of bias in for quasi‐randomised controlled trials (QRCTs), so we evaluated these as 'high risk of bias'. </p> </section> </section> <section id="CD008203-sec-0054"> <h5 class="title">B. We evaluated performance bias based on blinding of patients and people administering the treatment </h5> <p>Low risk (low risk of bias): the study described methods of blinding patients and people administering the treatment that were appropriate, so that participants and people administering the treatment did not know the exact treatment for each group until the blinding was broken; either participants or some key study personnel were not blinded but outcome assessment was blinded and the non‐blinding of others was unlikely to introduce bias. </p> <p>High risk (high risk of bias): no blinding was used for the participants and people administering the treatment. </p> <p>Unclear risk: insufficient information to permit judgment of 'low risk' or 'high risk', or no useful information obtained from the authors. </p> </section> <section id="CD008203-sec-0055"> <h5 class="title">C. Attrition bias was assessed by looking at the follow‐up to see if at least 80% of participants in all groups were included in the final analysis and an intention‐to‐treat analysis was used </h5> <p>Low risk (low risk of bias): &lt; 20% of participants withdrawn or lost to follow‐up because of side effects of treatment or other reasons, and also the reasons for why participants were lost and withdrawn were stated. Intention‐to‐treat analysis was specifically reported. </p> <p>High risk (high risk of bias): &gt; 20% of participants withdrawn or lost to follow‐up because of side effects of treatment or other reasons, and also the reasons why lost and withdrawn were not stated. Intention‐to‐treat analysis was not used if there were participants withdrawn or lost to follow‐up. </p> <p>Unclear risk: the losses to follow‐up were not reported or could not be judged from the article. </p> </section> <section id="CD008203-sec-0056"> <h5 class="title">D. Detection bias was assessed by evaluating the method of outcome assessment or blinding of outcome assessor </h5> <p>Low risk (low risk of bias): same methods of ascertainment for both groups and blinding of outcome assessor for assessing the outcomes. </p> <p>High risk (high risk of bias): different methods of ascertainment for both groups, or non‐blinding of outcome assessor for assessing the outcomes. </p> <p>Unclear risk: methods of ascertainment for both groups and blinding of outcome assessor for assessing the outcomes were not reported. </p> </section> <section id="CD008203-sec-0057"> <h5 class="title">E. Other biases were evaluated based on incomplete outcome data and selective outcome reporting </h5> <section id="CD008203-sec-0058"> <h6 class="title">1) Incomplete outcome data</h6> <p>Low risk (low risk of bias): no missing outcome data; missing outcome data balanced between groups with similar reasons and numbers lost for the missing data across groups; missing outcomes not enough to have a clinically relevant impact on the final results; missing data have been imputed using appropriate methods. </p> <p>High risk (high risk of bias): reason for missing outcome data related to true outcome, with either imbalance in numbers or reasons across the groups; missing outcomes enough to induce clinically relevant bias in the results; inappropriate methods were used to deal with the missing data. </p> <p>Unclear risk: cannot judge from the information obtained from the article.</p> </section> <section id="CD008203-sec-0059"> <h6 class="title">2) Selective outcome reporting</h6> <p>Low risk (low risk of bias): all the study's pre‐specified (primary and secondary) outcomes were reported in the article (if the study protocol was available) or all expected outcomes were mentioned in the published reports (the study protocol was not available). </p> <p>High risk (high risk of bias): one or more of the study's pre‐specified primary or expected outcomes failed to be included or was not reported. </p> <p>Unclear risk: there was insufficient information to judge 'low risk' or 'high risk'.</p> </section> </section> </section> <section id="CD008203-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>According to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008203-bbs2-0059" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we defined measures of treatment effects as follows. For dichotomous outcomes, we expressed results as odds ratio (OR) with 95% confidence interval (CI). If there were continuous scales of measurement to assess the effects of treatment, we used the mean difference (MD), or the standardised mean difference (SMD) if different scales were used. We analysed heterogeneity using the I<sup>2</sup> statistic based on N ‐ 1 degrees of freedom with an alpha of 0.05 for statistical significance (<a href="./references#CD008203-bbs2-0059" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008203-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>Individual participants were the unit of analysis because we intended to include individually randomised controlled trials with a parallel design. </p> </section> <section id="CD008203-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact all the authors (if e‐mails, telephone numbers, or fax details were available) of the original studies for the missing data. If the authors of the study did not respond within four or more weeks, we extracted all the available data from the publication. If data were missing because of dropping out of participants or losses to follow‐up, we planned to conduct a primary analysis based on the provided data and a sensitivity analysis with missing data imputed based on the worst‐case and best‐case scenarios. </p> </section> <section id="CD008203-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined heterogeneity among trials using the I<sup>2</sup> statistic. An I<sup>2</sup> statistic estimate greater than 50% was considered as substantial or considerable heterogeneity. Its causes were investigated by performing subgroup analyses, or sensitivity analyses by excluding studies thought to cause the heterogeneity. </p> </section> <section id="CD008203-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, we planned to assess reporting biases by using funnel plots.</p> </section> <section id="CD008203-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We used the software (RevMan 5) provided by The Cochrane Collaboration for statistical analysis, based on an intention‐to‐treat analysis. We considered meta‐analysis to determine the appropriate measure of effect if the search yielded a group of trials sufficiently homogeneous in terms of measured outcomes. According to the level of heterogeneity between trials, we used either a fixed‐effect or random‐effects model where appropriate. We pooled the outcomes and examined the differences between the two models. We planned to report the results qualitatively if we found significant heterogeneity and we could not find the reasons for the heterogeneity. </p> <section id="CD008203-sec-0066"> <h5 class="title">Trial sequential analysis</h5> <p>Meta‐analyses may result in type 1 errors due to sparse data and repeated significance testing when meta‐analyses are updated with new trials (<a href="./references#CD008203-bbs2-0046" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>). Trial sequential monitoring boundaries were determined using trial sequential analysis (TSA) software (<a href="./references#CD008203-bbs2-0070" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">Thorlund 2011</a>). If the cumulative Z‐curve crosses a trial sequential monitoring boundary (TSMB), a sufficient level of evidence is reached and no further trials may be needed. However, there is insufficient evidence to reach a conclusion if the cumulative Z‐curve does not cross the TSMB or does not surpass the futility boundaries before the required information size is reached (<a href="./references#CD008203-bbs2-0045" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , KrsticG , WetterslevJ , et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD007469.pub2] ">Bjelakovic 2014</a>). We also calculated a required information size, which is the least number of participants in a meta analysis to detect or reject a certain intervention effect, and adjusted the required information size to account for statistical between‐trial heterogeneity with a diversity adjustment factor (<a href="./references#CD008203-bbs2-0073" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). In our meta‐analysis, the diversity‐adjusted required information size was based on the event proportion in the control group; the assumption of a plausible RR reduction of 20%; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta‐analysis (<a href="./references#CD008203-bbs2-0073" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). </p> </section> </section> <section id="CD008203-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to undertake relevant subgroup analyses of the review data. We conducted subgroup analysis for different ages, gender and population (healthy people versus people considered to be at risk). </p> </section> <section id="CD008203-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p>We used sensitivity analysis to explore the impact of missing data or different studies on the stability of the treatment effect. </p> <section id="CD008203-sec-0069"> <h5 class="title">Summary of findings table</h5> <p>We employed the GRADE approach to interpret findings (<a href="./references#CD008203-bbs2-0055" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>), and the GRADE profiler (GRADEPRO) allowed us to import data from Review Manager 5.3 to create a summary of findings table. This table provides outcome‐specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes that we considered, given our trial sequential analyses (<a href="./references#CD008203-bbs2-0045" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , KrsticG , WetterslevJ , et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD007469.pub2] ">Bjelakovic 2014</a>). The following outcomes were included in the summary of findings table: all VTE, PE, DVT, MI, stroke, death and serious adverse events. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008203-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008203-sec-0070"></div> <section id="CD008203-sec-0071"> <h3 class="title">Description of studies</h3> <section id="CD008203-sec-0072"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD008203-fig-0002">Figure 2</a> for details of the search results. </p> <div class="figure" id="CD008203-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008203-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008203-sec-0073"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD008203-sec-0111" title="">Characteristics of included studies</a>. </p> <p>No additional studies were included in this update. There is one included study (<a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>), which investigated rosuvastatin. This study used rosuvastatin 20 mg daily for healthy people aged 50 years and older without a history of cardiovascular or cerebrovascular events. Characteristics of the included study are presented in the <a href="./references#CD008203-sec-0111" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008203-sec-0074"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD008203-sec-0112" title="">Characteristics of excluded studies</a>. </p> <p>For this update there were 24 additional studies excluded (<a href="./references#CD008203-bbs2-0002" title="DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. ">ACCEPT‐D</a>; <a href="./references#CD008203-bbs2-0003" title="DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287‐93. DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615‐22. ">AFCAPS/TexCAPS</a>; <a href="./references#CD008203-bbs2-0004" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , Kwiterovich , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62(17):1575‐9. BodenW , E , ProbstfieldJ , L . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: Results from the AIM‐HIGH trial. Circulation2011;124(21):2370. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relation of lipoprotein levels to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes (AIM‐HIGH) trial. Circulation2012;126(21 Suppl 1):A14501. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , Anderson , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44(10):2688‐93. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM‐HIGH). American Heart Journal2011;161(3):471‐7. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161(3):538‐43. ">AIM‐HIGH</a>; <a href="./references#CD008203-bbs2-0005" title="ChanKL , TeoK , DumesnilJG , NiA , TamJ , ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation2010;121(2):306‐14. ChanKL , TeoK , TamJ , DumesnilJG , Astronomer Investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. American Heart Journal2007;153(6):925‐31. ">ASTRONOMER</a>; <a href="./references#CD008203-bbs2-0006" title="CaramelliB , DurazzoA , IkeokaD , DeBernocheC , MonachiniM , Puech LeaoP , et al. Short‐term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no:086]. Atherosclerosis Supplements2002; Vol. 3:83. ">Caramelli 2002</a>; <a href="./references#CD008203-bbs2-0007" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet2004;364(9435):685‐96. ColhounHM , ThomasonMJ , MacknessMI , MatonSM , BetteridgeDJ , DurringtonPN , et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Medicine2002;19(3):201‐11. ">CARDS</a>; <a href="./references#CD008203-bbs2-0008" title="ChiCTR‐TNRC‐08000263 . The study of the intervention with statin on PE and CTEPH. http://apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR‐TNRC‐08000263. ">ChiCTR‐TNRC‐08000263</a>; <a href="./references#CD008203-bbs2-0009" title="SchoutenO , HoeksSE , VouteMT , BoersmaE , VerhagenHJ , PoldermansD . Long‐term benefit of perioperative statin use in patients undergoing vascular surgery: Results from the DECREASE III trial. Journal of Vascular Surgery2011;53(6):20S‐1S. ">DECREASE III</a>; <a href="./references#CD008203-bbs2-0011" title="Baylor College of Medicine. Effectiveness of intensive lipid modification medication in preventing the progression of peripheral arterial disease (The ELIMIT Study). http://clinicaltrials.gov/show/NCT00687076. BrunnerG , YangEY , KumarA , SunW , ViraniSS , NegiSI , et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis2013;231(2):371‐7. SaundersJ , NambiV , KimballKT , ViraniSS , MorrisettJD , LumsdenAB , et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of Vascular Surgery2011;53(3):668‐75. ">ELIMIT</a>; <a href="./references#CD008203-bbs2-0012" title="GeYY , ChengJQ , XiWJ , XuY , KangYM . Effects of ulinastatin on coagulation function and deep vein thrombosis in patients undergoing hip joint replacement. Zhonghua Wai Ke Za Zhi2011;49(9):816‐9. ">Ge 2011</a>; <a href="./references#CD008203-bbs2-0013" title="HaakE , AbletshauserC , WeberS , GoedickeC , MartinN , HermannsN , et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis2001;155(2):395‐401. ">Haak 2001</a>; <a href="./references#CD008203-bbs2-0015" title="ArmitageJ , LandmesserU . HPS2‐THRIVE: Treatment of HDL to reduce the incidence of vascular events. ESC Congress 2012. http://www.escardio.org/congresses/esc‐2012/congress‐reports/Pages/709‐4‐HPS2‐THRIVE.aspx#.VCQj0Y2t‐p0. HPS2‐THRIVE Collaborative Group. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. LiJ , LandrayMJ , CollinsR , ArmitageJ , BaigentC , ChenZ , et al. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: Trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. ">HPS2‐THRIVE</a>; <a href="./references#CD008203-bbs2-0017" title="JeongHC , AhnY , HongYJ , KimJH , JeongMH , KimYJ , et al. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high‐sensitivity C‐reactive protein. International Journal of Cardiology2013;167(5):1848‐53. ">Jeong 2013</a>; <a href="./references#CD008203-bbs2-0020" title="FeldmanHH , DoodyRS , KivipeltoM , SparksDL , WatersDD , JonesRW , et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology2010;74(12):956‐64. JonesRW , KivipeltoM , FeldmanH , SparksL , DoodyR , WatersDD , et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's &amp; Dementia2008;4(2):145‐53. ">LEADe</a>; <a href="./references#CD008203-bbs2-0021" title="LiuB , CaoHM , LiGY , LiuM , FengJ , LiJ , et al. Effects of rosuvastatin versus atorvastatin on rho‐associated coiled‐coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Journal of International Medical Research2011;39(6):2314‐22. ">Liu 2011</a>; <a href="./references#CD008203-bbs2-0022" title="NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155‐63. ">MEGA</a>; <a href="./references#CD008203-bbs2-0023" title="CrouseJR3rd , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis‐‐the rationale and methodology of the METEOR study. Cardiovascular Drugs and Therapy2004;18(3):231‐8. CrouseJR3rd , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima‐media thickness in low‐risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344‐53. ">METEOR</a>; <a href="./references#CD008203-bbs2-0025" title="HoshinaK , NemotoM , HashimotoT , MiuraS , UrabeG , NakazawaT , et al. Study Design of PROCEDURE Study. A randomized comparison of the dose‐dependent effects of pitavastatin in patients with abdominal aortic aneurysm with massive aortic atheroma: prevention of cholesterol embolization during endovascular and open aneurysm repair with pitavastatin (PROCEDURE) study. Annals of Vascular Disiseases2013;6(1):62‐6. ">PROCEDURE</a>; <a href="./references#CD008203-bbs2-0026" title="FreemanDJ , RobertsonM , BrownEA , RumleyA , TobiasES , FrölichM , et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics2011;11:8. ">PROSPER</a>; <a href="./references#CD008203-bbs2-0028" title="MacchiaA , LaffayeN , ComignaniPD , Cornejo PucciE , IgarzabalC , ScazziotaAS , et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One2012;7(3):e32894. ">RATIONAL</a>; <a href="./references#CD008203-bbs2-0030" title="RosenJB , JimenezJG , PiragsV , VidesH , HansonME , MassaadR , et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid‐lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes and Vascular Disease Research2013;10(3):277‐86. ">Rosen 2013</a>; <a href="./references#CD008203-bbs2-0031" title="ShaiA , RennertHS , RennertG , SagiS , LeviovM , LavieO . Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecologic Oncology2014;133(2):304‐8. ">Shai 2014</a>; <a href="./references#CD008203-bbs2-0035" title="van derLooB , SpringS , KoppensteinerR . High‐dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clinical Hemorheology and Microcirculation2011;47(4):241‐51. ">van der Loo 2011</a>; <a href="./references#CD008203-bbs2-0036" title="WestAMA . Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010:192. ">West 2010</a>). This made a total of 36 excluded studies (<a href="./references#CD008203-bbs2-0002" title="DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. ">ACCEPT‐D</a>; <a href="./references#CD008203-bbs2-0003" title="DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287‐93. DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615‐22. ">AFCAPS/TexCAPS</a>; <a href="./references#CD008203-bbs2-0004" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , Kwiterovich , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62(17):1575‐9. BodenW , E , ProbstfieldJ , L . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: Results from the AIM‐HIGH trial. Circulation2011;124(21):2370. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relation of lipoprotein levels to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes (AIM‐HIGH) trial. Circulation2012;126(21 Suppl 1):A14501. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , Anderson , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44(10):2688‐93. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM‐HIGH). American Heart Journal2011;161(3):471‐7. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161(3):538‐43. ">AIM‐HIGH</a>; <a href="./references#CD008203-bbs2-0005" title="ChanKL , TeoK , DumesnilJG , NiA , TamJ , ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation2010;121(2):306‐14. ChanKL , TeoK , TamJ , DumesnilJG , Astronomer Investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. American Heart Journal2007;153(6):925‐31. ">ASTRONOMER</a>; <a href="./references#CD008203-bbs2-0006" title="CaramelliB , DurazzoA , IkeokaD , DeBernocheC , MonachiniM , Puech LeaoP , et al. Short‐term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no:086]. Atherosclerosis Supplements2002; Vol. 3:83. ">Caramelli 2002</a>; <a href="./references#CD008203-bbs2-0007" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet2004;364(9435):685‐96. ColhounHM , ThomasonMJ , MacknessMI , MatonSM , BetteridgeDJ , DurringtonPN , et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Medicine2002;19(3):201‐11. ">CARDS</a>; <a href="./references#CD008203-bbs2-0008" title="ChiCTR‐TNRC‐08000263 . The study of the intervention with statin on PE and CTEPH. http://apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR‐TNRC‐08000263. ">ChiCTR‐TNRC‐08000263</a>; <a href="./references#CD008203-bbs2-0009" title="SchoutenO , HoeksSE , VouteMT , BoersmaE , VerhagenHJ , PoldermansD . Long‐term benefit of perioperative statin use in patients undergoing vascular surgery: Results from the DECREASE III trial. Journal of Vascular Surgery2011;53(6):20S‐1S. ">DECREASE III</a>; <a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a>; <a href="./references#CD008203-bbs2-0011" title="Baylor College of Medicine. Effectiveness of intensive lipid modification medication in preventing the progression of peripheral arterial disease (The ELIMIT Study). http://clinicaltrials.gov/show/NCT00687076. BrunnerG , YangEY , KumarA , SunW , ViraniSS , NegiSI , et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis2013;231(2):371‐7. SaundersJ , NambiV , KimballKT , ViraniSS , MorrisettJD , LumsdenAB , et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of Vascular Surgery2011;53(3):668‐75. ">ELIMIT</a>; <a href="./references#CD008203-bbs2-0012" title="GeYY , ChengJQ , XiWJ , XuY , KangYM . Effects of ulinastatin on coagulation function and deep vein thrombosis in patients undergoing hip joint replacement. Zhonghua Wai Ke Za Zhi2011;49(9):816‐9. ">Ge 2011</a>; <a href="./references#CD008203-bbs2-0013" title="HaakE , AbletshauserC , WeberS , GoedickeC , MartinN , HermannsN , et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis2001;155(2):395‐401. ">Haak 2001</a>; <a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a>; <a href="./references#CD008203-bbs2-0015" title="ArmitageJ , LandmesserU . HPS2‐THRIVE: Treatment of HDL to reduce the incidence of vascular events. ESC Congress 2012. http://www.escardio.org/congresses/esc‐2012/congress‐reports/Pages/709‐4‐HPS2‐THRIVE.aspx#.VCQj0Y2t‐p0. HPS2‐THRIVE Collaborative Group. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. LiJ , LandrayMJ , CollinsR , ArmitageJ , BaigentC , ChenZ , et al. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: Trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. ">HPS2‐THRIVE</a>; <a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a>; <a href="./references#CD008203-bbs2-0017" title="JeongHC , AhnY , HongYJ , KimJH , JeongMH , KimYJ , et al. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high‐sensitivity C‐reactive protein. International Journal of Cardiology2013;167(5):1848‐53. ">Jeong 2013</a>; <a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a>; <a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a>; <a href="./references#CD008203-bbs2-0020" title="FeldmanHH , DoodyRS , KivipeltoM , SparksDL , WatersDD , JonesRW , et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology2010;74(12):956‐64. JonesRW , KivipeltoM , FeldmanH , SparksL , DoodyR , WatersDD , et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's &amp; Dementia2008;4(2):145‐53. ">LEADe</a>; <a href="./references#CD008203-bbs2-0021" title="LiuB , CaoHM , LiGY , LiuM , FengJ , LiJ , et al. Effects of rosuvastatin versus atorvastatin on rho‐associated coiled‐coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Journal of International Medical Research2011;39(6):2314‐22. ">Liu 2011</a>; <a href="./references#CD008203-bbs2-0022" title="NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155‐63. ">MEGA</a>; <a href="./references#CD008203-bbs2-0023" title="CrouseJR3rd , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis‐‐the rationale and methodology of the METEOR study. Cardiovascular Drugs and Therapy2004;18(3):231‐8. CrouseJR3rd , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima‐media thickness in low‐risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344‐53. ">METEOR</a>; <a href="./references#CD008203-bbs2-0024" title="Università degli Studidell'Insubria . The effect of satins on d‐dimer levels in patients with a previous venous thromboembolic event. http://clinicaltrials.gov/ct2/show/NCT00437892. ">NCT00437892</a>; <a href="./references#CD008203-bbs2-0025" title="HoshinaK , NemotoM , HashimotoT , MiuraS , UrabeG , NakazawaT , et al. Study Design of PROCEDURE Study. A randomized comparison of the dose‐dependent effects of pitavastatin in patients with abdominal aortic aneurysm with massive aortic atheroma: prevention of cholesterol embolization during endovascular and open aneurysm repair with pitavastatin (PROCEDURE) study. Annals of Vascular Disiseases2013;6(1):62‐6. ">PROCEDURE</a>; <a href="./references#CD008203-bbs2-0026" title="FreemanDJ , RobertsonM , BrownEA , RumleyA , TobiasES , FrölichM , et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics2011;11:8. ">PROSPER</a>; <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a>; <a href="./references#CD008203-bbs2-0028" title="MacchiaA , LaffayeN , ComignaniPD , Cornejo PucciE , IgarzabalC , ScazziotaAS , et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One2012;7(3):e32894. ">RATIONAL</a>; <a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>; <a href="./references#CD008203-bbs2-0030" title="RosenJB , JimenezJG , PiragsV , VidesH , HansonME , MassaadR , et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid‐lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes and Vascular Disease Research2013;10(3):277‐86. ">Rosen 2013</a>; <a href="./references#CD008203-bbs2-0031" title="ShaiA , RennertHS , RennertG , SagiS , LeviovM , LavieO . Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecologic Oncology2014;133(2):304‐8. ">Shai 2014</a>; <a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a>; <a href="./references#CD008203-bbs2-0033" title="StangierJ , RathgenK , StahleH , ReseskiK , KornickeT , RothW . Co‐administration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. American Journal of Cardiovascular Drugs2009;9(1):59‐68. ">Stangier 2009</a>; <a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a>; <a href="./references#CD008203-bbs2-0035" title="van derLooB , SpringS , KoppensteinerR . High‐dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clinical Hemorheology and Microcirculation2011;47(4):241‐51. ">van der Loo 2011</a>; <a href="./references#CD008203-bbs2-0036" title="WestAMA . Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010:192. ">West 2010</a>; <a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a>). Four reports which had previously been excluded were assessed as not relevant in this update. </p> <p>Eight of the excluded studies were case‐control studies (<a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a>; <a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a>; <a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a>; <a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a>; <a href="./references#CD008203-bbs2-0026" title="FreemanDJ , RobertsonM , BrownEA , RumleyA , TobiasES , FrölichM , et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics2011;11:8. ">PROSPER</a>; <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a>; <a href="./references#CD008203-bbs2-0031" title="ShaiA , RennertHS , RennertG , SagiS , LeviovM , LavieO . Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecologic Oncology2014;133(2):304‐8. ">Shai 2014</a>; <a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a>); five were cohort studies (<a href="./references#CD008203-bbs2-0008" title="ChiCTR‐TNRC‐08000263 . The study of the intervention with statin on PE and CTEPH. http://apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR‐TNRC‐08000263. ">ChiCTR‐TNRC‐08000263</a>; <a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a>; <a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>; <a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a>; <a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a>); 17 were not VTE primary prevention studies (<a href="./references#CD008203-bbs2-0005" title="ChanKL , TeoK , DumesnilJG , NiA , TamJ , ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation2010;121(2):306‐14. ChanKL , TeoK , TamJ , DumesnilJG , Astronomer Investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. American Heart Journal2007;153(6):925‐31. ">ASTRONOMER</a>; <a href="./references#CD008203-bbs2-0006" title="CaramelliB , DurazzoA , IkeokaD , DeBernocheC , MonachiniM , Puech LeaoP , et al. Short‐term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no:086]. Atherosclerosis Supplements2002; Vol. 3:83. ">Caramelli 2002;</a><a href="./references#CD008203-bbs2-0007" title="ColhounHM , BetteridgeDJ , DurringtonPN , HitmanGA , NeilHA , LivingstoneSJ , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet2004;364(9435):685‐96. ColhounHM , ThomasonMJ , MacknessMI , MatonSM , BetteridgeDJ , DurringtonPN , et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Medicine2002;19(3):201‐11. ">CARDS</a>; <a href="./references#CD008203-bbs2-0009" title="SchoutenO , HoeksSE , VouteMT , BoersmaE , VerhagenHJ , PoldermansD . Long‐term benefit of perioperative statin use in patients undergoing vascular surgery: Results from the DECREASE III trial. Journal of Vascular Surgery2011;53(6):20S‐1S. ">DECREASE III</a>; <a href="./references#CD008203-bbs2-0011" title="Baylor College of Medicine. Effectiveness of intensive lipid modification medication in preventing the progression of peripheral arterial disease (The ELIMIT Study). http://clinicaltrials.gov/show/NCT00687076. BrunnerG , YangEY , KumarA , SunW , ViraniSS , NegiSI , et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis2013;231(2):371‐7. SaundersJ , NambiV , KimballKT , ViraniSS , MorrisettJD , LumsdenAB , et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of Vascular Surgery2011;53(3):668‐75. ">ELIMIT</a>; <a href="./references#CD008203-bbs2-0012" title="GeYY , ChengJQ , XiWJ , XuY , KangYM . Effects of ulinastatin on coagulation function and deep vein thrombosis in patients undergoing hip joint replacement. Zhonghua Wai Ke Za Zhi2011;49(9):816‐9. ">Ge 2011</a>; <a href="./references#CD008203-bbs2-0013" title="HaakE , AbletshauserC , WeberS , GoedickeC , MartinN , HermannsN , et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis2001;155(2):395‐401. ">Haak 2001</a>; <a href="./references#CD008203-bbs2-0017" title="JeongHC , AhnY , HongYJ , KimJH , JeongMH , KimYJ , et al. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high‐sensitivity C‐reactive protein. International Journal of Cardiology2013;167(5):1848‐53. ">Jeong 2013</a>; <a href="./references#CD008203-bbs2-0021" title="LiuB , CaoHM , LiGY , LiuM , FengJ , LiJ , et al. Effects of rosuvastatin versus atorvastatin on rho‐associated coiled‐coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Journal of International Medical Research2011;39(6):2314‐22. ">Liu 2011</a>; <a href="./references#CD008203-bbs2-0022" title="NakamuraH , ArakawaK , ItakuraH , KitabatakeA , GotoY , ToyotaT , et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368(9542):1155‐63. ">MEGA</a>; <a href="./references#CD008203-bbs2-0023" title="CrouseJR3rd , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis‐‐the rationale and methodology of the METEOR study. Cardiovascular Drugs and Therapy2004;18(3):231‐8. CrouseJR3rd , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima‐media thickness in low‐risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344‐53. ">METEOR</a>; <a href="./references#CD008203-bbs2-0025" title="HoshinaK , NemotoM , HashimotoT , MiuraS , UrabeG , NakazawaT , et al. Study Design of PROCEDURE Study. A randomized comparison of the dose‐dependent effects of pitavastatin in patients with abdominal aortic aneurysm with massive aortic atheroma: prevention of cholesterol embolization during endovascular and open aneurysm repair with pitavastatin (PROCEDURE) study. Annals of Vascular Disiseases2013;6(1):62‐6. ">PROCEDURE</a>; <a href="./references#CD008203-bbs2-0028" title="MacchiaA , LaffayeN , ComignaniPD , Cornejo PucciE , IgarzabalC , ScazziotaAS , et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS One2012;7(3):e32894. ">RATIONAL</a>; <a href="./references#CD008203-bbs2-0030" title="RosenJB , JimenezJG , PiragsV , VidesH , HansonME , MassaadR , et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid‐lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes and Vascular Disease Research2013;10(3):277‐86. ">Rosen 2013</a>; <a href="./references#CD008203-bbs2-0033" title="StangierJ , RathgenK , StahleH , ReseskiK , KornickeT , RothW . Co‐administration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. American Journal of Cardiovascular Drugs2009;9(1):59‐68. ">Stangier 2009</a>; <a href="./references#CD008203-bbs2-0035" title="van derLooB , SpringS , KoppensteinerR . High‐dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clinical Hemorheology and Microcirculation2011;47(4):241‐51. ">van der Loo 2011</a>; <a href="./references#CD008203-bbs2-0024" title="Università degli Studidell'Insubria . The effect of satins on d‐dimer levels in patients with a previous venous thromboembolic event. http://clinicaltrials.gov/ct2/show/NCT00437892. ">NCT00437892</a>); and six studies focused on both statins and other interventions (<a href="./references#CD008203-bbs2-0002" title="DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. DeBerardisG , SaccoM , EvangelistaV , FilippiA , GiordaCB , TognoniG , et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT‐D): design of a randomized study of the efficacy of low‐dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials2007;8:21. ">ACCEPT‐D</a>; <a href="./references#CD008203-bbs2-0003" title="DownsJR , BeerePA , WhitneyE , ClearfieldM , WeisS , RochenJ , et al. Design &amp; rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology1997;80(3):287‐93. DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615‐22. ">AFCAPS/TexCAPS</a>; <a href="./references#CD008203-bbs2-0004" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , Kwiterovich , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62(17):1575‐9. BodenW , E , ProbstfieldJ , L . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: Results from the AIM‐HIGH trial. Circulation2011;124(21):2370. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relation of lipoprotein levels to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes (AIM‐HIGH) trial. Circulation2012;126(21 Suppl 1):A14501. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , Anderson , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44(10):2688‐93. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM‐HIGH). American Heart Journal2011;161(3):471‐7. The AIM‐HIGH Investigators. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161(3):538‐43. ">AIM‐HIGH</a>; <a href="./references#CD008203-bbs2-0015" title="ArmitageJ , LandmesserU . HPS2‐THRIVE: Treatment of HDL to reduce the incidence of vascular events. ESC Congress 2012. http://www.escardio.org/congresses/esc‐2012/congress‐reports/Pages/709‐4‐HPS2‐THRIVE.aspx#.VCQj0Y2t‐p0. HPS2‐THRIVE Collaborative Group. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. LiJ , LandrayMJ , CollinsR , ArmitageJ , BaigentC , ChenZ , et al. HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: Trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34(17):1279‐91. ">HPS2‐THRIVE</a>; <a href="./references#CD008203-bbs2-0020" title="FeldmanHH , DoodyRS , KivipeltoM , SparksDL , WatersDD , JonesRW , et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology2010;74(12):956‐64. JonesRW , KivipeltoM , FeldmanH , SparksL , DoodyR , WatersDD , et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's &amp; Dementia2008;4(2):145‐53. ">LEADe</a>; <a href="./references#CD008203-bbs2-0036" title="WestAMA . Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR. Journal of Cardiovascular Magnetic Resonance2010:192. ">West 2010</a>). </p> <p>For this update there were three additional ongoing studies (<a href="./references#CD008203-bbs2-0038" title="Yale University. High‐Dose Periop Statins for Prevention of DVT. http://clinicaltrials.gov/show/NCT00259662(accessed November 2014). ">NCT00259662</a>; <a href="./references#CD008203-bbs2-0040" title="Hallym University Medical Center. Re‐STOP DVT: Reload of high dose atorvastatin for preventing deep vein thrombosis in statin users. http://www.clinicaltrials.gov/ct2/show/NCT01063426(accessed November 2014). ">NCT01063426</a>; <a href="./references#CD008203-bbs2-0041" title="University of Vermont. Detecting the impact of statin therapy on lowering risk of venous thrombo‐embolic events (DISOLVE). http://clinicaltrials.gov/ct2/show/NCT01524653(accessed November 2014). ">NCT01524653</a>), making a total of four ongoing studies (<a href="./references#CD008203-bbs2-0038" title="Yale University. High‐Dose Periop Statins for Prevention of DVT. http://clinicaltrials.gov/show/NCT00259662(accessed November 2014). ">NCT00259662</a>; <a href="./references#CD008203-bbs2-0039" title="Hallym University Medical Center. Rosuvastatin for Preventing Deep Vein Thrombosis (STOP‐DVT). http://clinicaltrials.gov/ct2/show/results/NCT01021488 November 25, 2009. ParkWJ , JoSH , KimSA , KimHS , HanSJ , ChoiYJ , RhimCY . Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty ‐ a prospective randomized open‐label controlled trial. Contemporary Clinical Trials 201;32(5):779‐82. ">NCT01021488</a>; <a href="./references#CD008203-bbs2-0040" title="Hallym University Medical Center. Re‐STOP DVT: Reload of high dose atorvastatin for preventing deep vein thrombosis in statin users. http://www.clinicaltrials.gov/ct2/show/NCT01063426(accessed November 2014). ">NCT01063426</a>; <a href="./references#CD008203-bbs2-0041" title="University of Vermont. Detecting the impact of statin therapy on lowering risk of venous thrombo‐embolic events (DISOLVE). http://clinicaltrials.gov/ct2/show/NCT01524653(accessed November 2014). ">NCT01524653</a>). </p> </section> </section> <section id="CD008203-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment for the included study is presented in <a href="./references#CD008203-sec-0111" title="">Characteristics of included studies</a> and <a href="#CD008203-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008203-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008203-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008203-sec-0076"> <h4 class="title">Allocation</h4> <p>The method of randomisation was on the basis of a computer generated list. Randomisation was performed with the use of an interactive voice‐response system and was stratified according to centre (<a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>). </p> </section> <section id="CD008203-sec-0077"> <h4 class="title">Blinding</h4> <p>A closeout visit occurred after study termination, at which time participants were unblinded. All reported primary endpoints were adjudicated by an independent endpoint committee blinded to the randomised treatment assignment. Adverse events were monitored and reported in a blinded manner until the date of the closeout visit and discontinuation of therapy (<a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>). </p> </section> <section id="CD008203-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>We compared the study protocol and study publications and found no missed reporting of outcomes. Therefore, there were no incomplete outcome data in this included study. </p> </section> <section id="CD008203-sec-0079"> <h4 class="title">Selective reporting</h4> <p>We compared the study protocol and the study and we found that all pre‐specified outcomes were reported in the relevant publications. Therefore, there was no selective reporting in this included study. </p> </section> <section id="CD008203-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>The trial was financially supported by AstraZeneca. The authors of all publications reported that the sponsor collected the trial data and monitored the study sites but played no role in the conduct of the analyses or drafting of the manuscript (<a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>). Therefore, funding should not have introduced potential biases in this trial. </p> </section> </section> <section id="CD008203-sec-0081"> <h3 class="title" id="CD008203-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD008203-tbl-0001"><b>Summary of findings for the main comparison</b> Statin versus placebo for primary prevention of venous thromboembolism</a> </p> <p>As outlined in the protocol, we have presented the results for dichotomous outcomes using ORs with 95% CIs and for continuous outcomes using the mean difference (MD) with 95% CI, or the standardised mean difference (SMD) if different scales were used. </p> <section id="CD008203-sec-0082"> <h4 class="title">The rates of VTE</h4> <p>Symptomatic PE or DVT occurred in 94 participants during a median follow‐up time of 1.9 years. The rates of VTE were 0.18 and 0.32 events per 100 person‐years of follow‐up in the rosuvastatin and placebo groups, respectively (hazard ratio (HR) 0.57, 95% CI 0.37 to 0.86; P = 0.007). </p> <p>Our analysis showed that, compared with placebo, rosuvastatin could reduce the incidence of all cases of VTE (rosuvastatin 34/8901, placebo 60/8901; OR 0.57, 95% CI 0.37 to 0.86) (<a href="./references#CD008203-fig-0007" title="">Analysis 1.1</a>, <a href="#CD008203-fig-0004">Figure 4</a>), provoked VTE (rosuvastatin 15/8901, placebo 29/8901; OR 0.52, 95% CI 0.28 to 0.96) (<a href="./references#CD008203-fig-0008" title="">Analysis 1.2</a>), and DVT only (rosuvastatin 17/8901, placebo 38/8901; OR 0.45, 95% CI 0.25 to 0.79) (<a href="./references#CD008203-fig-0009" title="">Analysis 1.3</a>). There was no difference between rosuvastatin and placebo in the incidence of unprovoked VTE (rosuvastatin 19/8901, placebo 31/8901; OR 0.61, 95% CI 0.35 to 1.08) (<a href="./references#CD008203-fig-0010" title="">Analysis 1.4</a>) and PE (rosuvastatin 17/8901, placebo 22/8901; OR 0.77, 95% CI 0.41 to 1.46) (<a href="./references#CD008203-fig-0011" title="">Analysis 1.5</a>). </p> <div class="figure" id="CD008203-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.1 All cases of VTE." data-id="CD008203-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.1 All cases of VTE. </p> </div> </div> </div> <p>We found that, compared with placebo, rosuvastatin could reduce the incidence of all VTE in men (OR 0.50, 95% CI 0.30 to 0.84) (<a href="./references#CD008203-fig-0012" title="">Analysis 1.6</a>) and patients aged 50 to 69 years (OR 0.55, 95% CI 0.31 to 0.96) (<a href="./references#CD008203-fig-0013" title="">Analysis 1.7</a>) but there was no difference between rosuvastatin and placebo in the incidence of all VTE in women (OR 0.74, 95% CI 0.35 to 1.56) (<a href="./references#CD008203-fig-0012" title="">Analysis 1.6</a>) and patients aged 70 to 97 years (OR 0.59, 95% CI 0.31 to 1.11) (<a href="./references#CD008203-fig-0013" title="">Analysis 1.7</a>). </p> </section> <section id="CD008203-sec-0083"> <h4 class="title">The rates of cardiovascular and cerebrovascular events</h4> <p>From our analysis, we found that, compared with placebo, rosuvastatin could reduce the risk of cardiovascular events in a healthy population (OR 0.71, 95% CI 0.57 to 0.89) (<a href="./references#CD008203-fig-0014" title="">Analysis 1.8</a>), any MI (OR 0.45, 95% CI 0.30 to 0.69) (<a href="./references#CD008203-fig-0015" title="">Analysis 1.9</a>), any stroke (OR 0.51, 95% CI 0.34 to 0.78) (<a href="./references#CD008203-fig-0017" title="">Analysis 1.11</a>) and arterial revascularisation (OR 0.54, 95% CI 0.40 to 0.72) (<a href="./references#CD008203-fig-0019" title="">Analysis 1.13</a>). There was no difference between rosuvastatin and placebo in fatal MI (OR 1.50, 95% CI 0.53 to 4.22) (<a href="./references#CD008203-fig-0016" title="">Analysis 1.10</a>) and fatal stroke (OR 0.30, 95% CI 0.08 to 1.09) (<a href="./references#CD008203-fig-0018" title="">Analysis 1.12</a>). </p> </section> <section id="CD008203-sec-0084"> <h4 class="title">The rates of death</h4> <p>Rosuvastatin could reduce the incidence of any death (OR 0.80, 95% CI 0.66 to 0.96) (<a href="./references#CD008203-fig-0020" title="">Analysis 1.14</a>, <a href="#CD008203-fig-0005">Figure 5</a>) but there was no difference between rosuvastatin and placebo in the incidence of death after VTE (OR 0.50, 95% CI 0.20 to 1.24) (<a href="./references#CD008203-fig-0021" title="">Analysis 1.15</a>) or death resulting from cardiovascular causes (OR 0.76, 95% CI 0.42 to 1.38) (<a href="./references#CD008203-fig-0022" title="">Analysis 1.16</a>). </p> <div class="figure" id="CD008203-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Statin versus placebo, outcome: 1.14 Death." data-id="CD008203-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Statin versus placebo, outcome: 1.14 Death.</p> </div> </div> </div> </section> <section id="CD008203-sec-0085"> <h4 class="title">Adverse events</h4> <p>There was no difference between rosuvastatin and placebo in the incidence of any serious adverse event (OR 1.07, 95% CI 0.95 to 1.20) (<a href="./references#CD008203-fig-0023" title="">Analysis 1.17</a>, <a href="#CD008203-fig-0006">Figure 6</a>). Similar results were reported in hepatic disorder (OR 1.17, 95% CI 0.96 to 1.42) (<a href="./references#CD008203-fig-0024" title="">Analysis 1.18</a>); myopathy (OR 1.11, 95% CI 0.45 to 2.74) (<a href="./references#CD008203-fig-0025" title="">Analysis 1.19</a>); rhabdomyolysis (OR 3.00, 95% CI 0.12 to 73.66) (<a href="./references#CD008203-fig-0026" title="">Analysis 1.20</a>); renal disorder (OR 1.12, 95% CI 0.99 to 1.27) (<a href="./references#CD008203-fig-0027" title="">Analysis 1.21</a>); bleeding (OR 0.94, 95% CI 0.79 to 1.11) (<a href="./references#CD008203-fig-0028" title="">Analysis 1.22</a>); muscular weakness, stiffness or pain (OR 1.04, 95% CI 0.96 to 1.13) (<a href="./references#CD008203-fig-0029" title="">Analysis 1.23</a>); or gastrointestinal disorder (OR 1.03, 95% CI 0.96 to 1.11) (<a href="./references#CD008203-fig-0030" title="">Analysis 1.24</a>). </p> <div class="figure" id="CD008203-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.17 Any serious adverse event." data-id="CD008203-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.17 Any serious adverse event. </p> </div> </div> </div> <section id="CD008203-sec-0086"> <h5 class="title">Trial sequential analysis (TSA)</h5> <p><a href="./full#CD008203-fig-0001">Figure 1</a> showed the trial sequential analysis (TSA) results for the main outcome: the incidence of VTE. The cumulative Z‐curve crossed the trial sequential monitoring boundaries and the required information size was not reached. This suggests that evidence was sufficient, although the sample size was not large enough. TSA results for the remaining outcomes in the <a href="./full#CD008203-tbl-0001">summary of findings Table for the main comparison</a> are described in <a href="./appendices#CD008203-sec-0102">Appendix 3</a>. </p> </section> </section> <section id="CD008203-sec-0087"> <h4 class="title">Summary of findings</h4> <p>A summary of the results is presented in <a href="./full#CD008203-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008203-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008203-sec-0088"></div> <section id="CD008203-sec-0089"> <h3 class="title" id="CD008203-sec-0089">Summary of main results</h3> <p>Even though there are other statins that can be used for preventing VTE (<a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a>; <a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a>; <a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a>; <a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a>; <a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a>; <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009;</a><a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>; <a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a>; <a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a>; <a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a>), due to of a lack of RCTs evaluating the effects of statins in the primary prevention of VTE we only included one RCT of rosuvastatin (<a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>) in this systematic review. </p> <p>Our analysis showed that, compared with placebo, rosuvastatin could reduce the incidence of all cases of VTE and provoked VTE and DVT, but there was no difference between rosuvastatin and placebo in the incidence of unprovoked VTE or PE. We found that rosuvastatin could reduce the incidence of all VTE in men and patients aged 50 to 69 years but there was no difference between rosuvastatin and placebo in the incidence of all VTE in women or patients aged 70 to 97 years. Rosuvastatin could reduce the risk of any MI, any stroke, arterial revascularisation, and cardiovascular events, but there was no difference between rosuvastatin and placebo in the risk of fatal MI and fatal stroke. The incidence of any death was reduced with rosuvastatin but there was no difference between rosuvastatin and placebo in the incidence of death after VTE and confirmed deaths resulting from cardiovascular events. There was no difference between rosuvastatin and placebo in the incidence of any serious adverse events. Similar results were reported for adverse effects including bleeding, muscular weakness, stiffness or pain, myopathy, rhabdomyolysis, gastrointestinal disorders, renal disorders and hepatic disorders. </p> </section> <section id="CD008203-sec-0090"> <h3 class="title" id="CD008203-sec-0090">Overall completeness and applicability of evidence</h3> <p>Only one RCT that included 17,802 healthy participants assessed the efficacy of statins for the prevention of VTE. After subgroup analysis, it appears that some participants with risk factors for VTE could benefit from rosuvastatin treatment, but the results of this study might not apply to patients with risk factors which were not investigated by this trial. In addition, this trial was stopped early on the advice of the independent data and safety monitoring board, after a median follow‐up of less than two years, based on the size and precision of the observed treatment benefit as well as effects on the rates of death in patients treated with rosuvastatin compared with placebo. As a result, the effects of longer‐term therapy cannot be ascertained. Rosuvastatin was not associated with adverse events such as bleeding, muscular weakness, stiffness or pain, or gastrointestinal disorders. Such adverse events are of importance to patients and these adverse events might force patients to stop taking rosuvastatin. Therefore, even though rosuvastatin showed exciting beneficial effects for preventing VTE in some patient groups, there are limitations to applying the results to other patient groups. </p> <p>Even though all the data from this review came from just one study, the participants were from 26 countries worldwide. However there were very few participants in some countries, for example Uruguay, Switzerland, Romania and Chile. Most of the participants were from Canada, South Africa, United Kingdom and the United States. As a result, the results represented only a part of the world. </p> <p>A recent systematic review (<a href="./references#CD008203-bbs2-0068" title="RodriguezAL , WojcikBM , WrobleskiSK , MyersDD , WakefieldTW , DiazJA . Statins, inflammation and deep vein thrombosis: A systematic review. Journal of Thrombosis and Thrombolysis2012;33(4):371‐82. ">Rodriguez 2012</a>) showed that statin therapy reduces IL‐6 induced expression of CRP and MCP‐1, which has been linked to vein wall fibrosis, promoting post‐thrombotic syndrome (PTS) and recurrent DVT in patients. This could explain why statins may reduce the incidence of VTE, but the available evidence about statins in the primary prevention of VTE is limited. Due to insufficient evidence, we could not conclude that statin use can reduce the incidence of VTE. However, based on the <a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a>, statin use by the general healthy population may reduce the risk of VTE. </p> </section> <section id="CD008203-sec-0091"> <h3 class="title" id="CD008203-sec-0091">Quality of the evidence</h3> <p>The one included study is a randomised, double‐blind, placebo‐controlled trial which used a computer to generate the randomisation sequence; the random allocation sequence was implemented with the use of an interactive voice‐response system. All the primary endpoints that were evaluated were adjudicated by an independent endpoint committee blinded to the randomised treatment assignment. We compared the study protocol and study publications and found no missing outcomes or selective reporting. Even though the trial was financially supported by AstraZeneca, the authors of all publications reported that the sponsor collected the trial data and monitored the study sites but played no role in the conduct of the analyses or drafting of the manuscripts. As a result, funding should not have introduced biases in this trial. In addition, there was no indirectness of evidence (indirect population, intervention, control, outcomes) (<a href="./references#CD008203-bbs2-0059" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses) (<a href="./references#CD008203-bbs2-0059" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), or high probability of publication bias in this study. The very few limitations in the design and implementation of the study therefore suggest a low likelihood of bias. However, for all outcomes in the <a href="./full#CD008203-tbl-0001">summary of findings Table for the main comparison</a> (<a href="./appendices#CD008203-sec-0102">Appendix 3</a>) the required sample size was not achieved, so the quality of the evidence for each outcome was downgraded for imprecision (<a href="./references#CD008203-bbs2-0056" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011</a>). As a result, all outcomes in the <a href="./full#CD008203-tbl-0001">summary of findings Table for the main comparison</a> had moderate levels of quality of evidence. </p> </section> <section id="CD008203-sec-0092"> <h3 class="title" id="CD008203-sec-0092">Potential biases in the review process</h3> <p>Extensive electronic searches were conducted to search for relevant articles. As the databases we searched mostly included papers in the English language, it is possible that papers describing trials of statins for preventing VTE in other languages may not have been located. This review included published data only, and the unpublished data of the ongoing studies was not available. As our meta‐analysis was based on published data, there may be selective reporting biases. This review is not a comprehensive review of the effects of statins on cardiovascular outcomes as we assessed these outcomes based on studies that assessed statins in the primary prevention of VTE. So there might be selection bias for the cardiovascular outcomes. </p> </section> <section id="CD008203-sec-0093"> <h3 class="title" id="CD008203-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>Our results were consistent with other meta‐analyses, which showed that statin use could reduce the incidence of all cases of VTE, provoked VTE, and DVT only; but that it did not reduce the incidence of unprovoked VTE and PE (<a href="./references#CD008203-bbs2-0042" title="AgarwalV , PhungOJ , TongbramV , BhardwajA , ColemanCI . Statin use and the prevention of venous thromboembolism: A meta‐analysis. International Journal of Clinical Practice2010;10:1375‐83. ">Agarwal 2010</a>; <a href="./references#CD008203-bbs2-0063" title="PaiM , EvansNS , ShahSJ , GreenD , CookD , CrowtherMA . Statins in the prevention of venous thromboembolism: A meta‐analysis of observational studies. Thrombosis Research2011;128(5):422‐30. ">Pai 2011</a>; <a href="./references#CD008203-bbs2-0067" title="RayJG . Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Current Opinion in Pulmonary Medicine2003;9(5):378‐84. ">Ray 2003b</a>; <a href="./references#CD008203-bbs2-0069" title="SquizzatoA , GalliM , RomualdiE , DentaliF , KamphuisenPW , GuastiL , et al. Statins, fibrates, and venous thromboembolism: A meta‐analysis. European Heart Journal2010;31(10):1248‐56. ">Squizzato 2010</a>). These results are consistent with case‐control studies and cohort studies showing reduced risks of VTE (<a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a>; <a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a>; <a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a>; <a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a>; <a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a>; <a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a>; <a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a>; <a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a>). In a study by <a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a>, simvastatin was associated with a reduced risk of PE (OR 0.51, 95% CI 0.29 to 0.91) but pravastatin was not (OR 1.85, 95% CI 0.65 to 5.26). In a retrospective cohort study (<a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a>), current statin use was not associated with a reduced risk of idiopathic VTE (RR 0.8, 95% CI 0.3 to 2.7). However, another meta‐analysis of published and unpublished evidence from RCTs showed that allocation to statin therapy did not significantly reduce the risk of VTE events, with no evidence of heterogeneity between effects on DVT and effects on PE (<a href="./references#CD008203-bbs2-0064" title="RahimiK , BhalaN , KamphuisenP , EmbersonJ , Biere‐RafiS , KraneV , et al. Effect of statins on venous thromboembolic events: a meta‐analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine2012;9(9):e1001310. ">Rahimi 2012</a>). It is possible that including unpublished data on statin use in the primary prevention of VTE might change the effect size (<a href="./references#CD008203-bbs2-0064" title="RahimiK , BhalaN , KamphuisenP , EmbersonJ , Biere‐RafiS , KraneV , et al. Effect of statins on venous thromboembolic events: a meta‐analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine2012;9(9):e1001310. ">Rahimi 2012</a>). Our meta‐analysis only included one RCT that compared a statin with placebo in the primary prevention of VTE, and the study showed that statin use could reduce the incidence of VTE. These conflicting results mean that we still need further well designed and reported VTE primary prevention studies to test the prevention effects of statins. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008203-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis results for the incidence of VTE." data-id="CD008203-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial sequential analysis results for the incidence of VTE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008203-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008203-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.1 All cases of VTE." data-id="CD008203-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.1 All cases of VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Statin versus placebo, outcome: 1.14 Death." data-id="CD008203-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Statin versus placebo, outcome: 1.14 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.17 Any serious adverse event." data-id="CD008203-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rosuvastatin versus placebo, outcome: 1.17 Any serious adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 1 All cases of VTE." data-id="CD008203-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 1 All cases of VTE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 2 Provoked VTE." data-id="CD008203-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 2 Provoked VTE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 3 Deep vein thrombosis." data-id="CD008203-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 3 Deep vein thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 4 Unprovoked VTE." data-id="CD008203-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 4 Unprovoked VTE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 5 Pulmonary embolism." data-id="CD008203-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 5 Pulmonary embolism.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 6 All cases of VTE ‐ gender." data-id="CD008203-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 6 All cases of VTE ‐ gender.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 7 All cases of VTE ‐ age." data-id="CD008203-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 7 All cases of VTE ‐ age.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 8 Cardiovascular events." data-id="CD008203-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 8 Cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 9 Any MI." data-id="CD008203-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 9 Any MI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 10 Fatal MI." data-id="CD008203-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 10 Fatal MI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 11 Any stroke." data-id="CD008203-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 11 Any stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 12 Fatal stroke." data-id="CD008203-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 12 Fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 13 Arterial revascularisation." data-id="CD008203-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 13 Arterial revascularisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-14.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 14 Death." data-id="CD008203-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 14 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 15 Death after VTE." data-id="CD008203-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 15 Death after VTE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 16 Confirmed death resulting from cardiovascular causes." data-id="CD008203-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 16 Confirmed death resulting from cardiovascular causes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-17.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 17 Any serious adverse event." data-id="CD008203-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 17 Any serious adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 18 Hepatic disorder." data-id="CD008203-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 18 Hepatic disorder.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 19 Myopathy." data-id="CD008203-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 19 Myopathy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 20 Rhabdomyolysis." data-id="CD008203-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 20 Rhabdomyolysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 21 Renal disorder." data-id="CD008203-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 21 Renal disorder.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 22 Bleeding." data-id="CD008203-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 22 Bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 23 Muscular weakness, stiffness, or pain." data-id="CD008203-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 23 Muscular weakness, stiffness, or pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008203-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/urn:x-wiley:14651858:media:CD008203:CD008203-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_t/tCD008203-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Statin versus placebo, Outcome 24 Gastrointestinal disorder." data-id="CD008203-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Statin versus placebo, Outcome 24 Gastrointestinal disorder.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/media/CDSR/CD008203/image_n/nCD008203-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008203-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Statin versus placebo for primary prevention of venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Statin versus placebo for primary prevention of venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (&lt; 130 mg/dL)<br/> <b>Settings:</b> 1315 sites in 26 countries on 4 continents, including North and South America, Europe, and Africa<br/> <b>Intervention:</b> rosuvastatin 20 mg daily versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Statin versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All cases of VTE</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.57</b> <br/> (0.37 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./full#CD008203-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary embolism</b> <br/> Follow‐up: mean 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Deep vein thrombosis</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any MI</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.45</b> <br/> (0.3 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (2 to 5) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any stroke</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.51</b> <br/> (0.34 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> <br/> (2 to 5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Death</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.8</b> <br/> (0.66 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (18 to 27) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (19 to 27) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Any serious adverse event</b> <br/> Follow‐up: median 1.9 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.07</b> <br/> (0.95 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17802<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./appendices#CD008203-sec-0102">Appendix 3</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (63 to 78) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (63 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Total sample size is lower than the calculated optimal information size (OIS). Therefore the evidence was downgraded based on imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Statin versus placebo for primary prevention of venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008203-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published studies reporting the frequency of venous thromboembolism (VTE) in statin users and nonusers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Result</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0001" title='AstraZeneca . A randomized, double‐blind, placebo controlled, multicenter, phase 3 study of rosuvastatin (CRESTOR®) 20 mg in the prevention of cardiovascular events among subjects with low levels of LDL cholesterol and elevated levels of C‐reactive protein. http://clinicaltrials.gov/ct2/show/NCT00239681. EverettBM , GlynnRJ , MacFadyenJG , RidkerPM . Rosuvastatin in the prevention of stroke among men and women with elevated levels of C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation2010;121(1):143‐50. FonsecaFA , IzarMC . Primary prevention of vascular events in patients with high levels of C‐reactive protein: the JUPITER study. Expert Review Cardiovascular Therapy2009;7(9):1041‐56. GlynnRJ , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine2009;360(18):1851‐61. GlynnRJ , KoenigW , NordestgaardBG , ShepherdJ , RidkerPM . Rosuvastatin for primary prevention in older persons with elevated C‐reactive protein and low to average low‐density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Annals of Internal Medicine2010;152(8):488‐96, W174. HsiaJ , MacFadyenJG , MonyakJ , RidkerPM . Cardiovascular event reduction and adverse events among subjects attaining low‐density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology2011;57:1666‐75. KerstAJFA . A randomised study of efficacy of statins in the prevention of venous thromboembolism. Geneesmiddelenbulletin.2009;43:104‐5. KoenigW , RidkerPM . Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &gt;/= 5% or Framingham risk &gt;20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal2011;32(1):75‐83. MoraS , GlynnRJ , HsiaJ , MacFadyenJG , GenestJ , RidkerPM . Statins for the primary prevention of cardiovascular events in women with elevated high‐sensitivity C‐reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta‐analysis of women from primary prevention trials. Circulation2010;121(9):1069‐77. RidkerPM , DanielsonE , FonsecaF , GenestJ , GottoAM , KasteleinJJ , et al. Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C‐reactive protein: the JUPITER trial. Circulation2008; Vol. 118, issue 22:2310. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009;373(9670):1175‐82. RidkerPM , DanielsonE , FonsecaFA , GenestJ , GottoAMJr , KasteleinJJ , et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. New England Journal of Medicine2008;359(21):2195‐207. RidkerPM , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , KhurmiNS , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo‐controlled primary prevention trial of statin therapy among individuals with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein. American Journal of Cardiology2007;100(11):1659‐64. RidkerPM , GenestJ , BoekholdtSM , LibbyP , GottoAM , NordestgaardBG , et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet2010;376(9738):333‐9. RidkerPM , JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation2003;108(19):2292‐7. RidkerPM , MacFadyenJ , CressmanM , GlynnRJ . Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high‐sensitivity C‐reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention‐an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology2010;55(12):1266‐73. RidkerPM , MacFadyenJG , FonsecaFA , GenestJ , GottoAM , KasteleinJJ , et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation. Cardiovascular Quality &amp; Outcomes2009;2(6):616‐23. RidkerPM , MacFadyenJG , NordestgaardBG , KoenigW , KasteleinJJ , GenestJ , et al. Rosuvastatin for primary prevention among individuals with elevated high‐sensitivity C‐reactive protein and 5% to 10% and 10% to 20% 10‐year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality &amp; Outcomes2010;3(5):447‐52. RidkerPM , PradhanA , MacFadyenJG , LibbyP , GlynnRJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet2012;380(9841):565‐71. SlejkoJF , PageRL , SullivanPW . Cost‐effectiveness of statin therapy for vascular event prevention in adults with elevated C‐reactive protein: implications of JUPITER. Current Medical Research and Opinion2010;26(10):2485‐97. '>JUPITER trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (secondary outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8901/8901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosuvastatin 20 mg daily versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.57 (95% CI 0.37 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0027" title="RamcharanAS , vanStralenKJ , SnoepJD , Mantel‐TeeuwisseAK , RosendaalFR , DoggenCJ . HMG‐CoA‐reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis2009;7(4):514‐20. ">Ramcharan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4538/5914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55 (95% CI 0.46 to 0.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0034" title="SørensenHT , Horvath‐PuhoE , SøgaardKK , ChristensenS , JohnsenSP , ThomsenRW , et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study. Journal of Thrombosis and Haemostasis2009;7(4):521‐8. ">Sørensen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5824/58240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (95% CI 0.63 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0032" title="SmeethL , DouglasI , HallAJ , HubbardR , EvansS . Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology2009;67(1):99‐109. ">Smeeth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129,288/600,241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR no statin versus statin 1.18 (95% CI 1.06 to 1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008203-bbs2-0018" title="LacutK , OgerE , LeGalG , CouturaudF , LouisS , LeroyerC , et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case‐control study. Fundamental and Clinical Pharmacology2004;18(4):477‐82. ">Lacut 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377/377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.42 (95% CI 0.23 to 0.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0019" title="LacutK , LeGalG , AbalainJH , MottierD , OgerE . Differential associations between lipid‐lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?. Thrombosis Research2008;122(3):314‐9. ">Lacut 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677/677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53 (95% CI 0.37 to 0.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0014" title="HerringtonDM , VittinghoffE , LinF , FongJ , HarrisF , HunninghakeD , et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation2002;105(25):2962‐7. ">HERS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised comparison (part of HERS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1712/1051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.40 (95% CI 0.18 to 0.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0037" title="YangCC , JickSS , JickH . Statins and the risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology2002;53(1):101‐5. ">Yang 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,993/61,100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR current/recent statin use 0.8 (95% CI 0.3 to 2.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0029" title="RayJG , MamdaniM , TsuyukiRT , AndersonDR , YeoEL , LaupacisA . Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine2001;161(11):1405‐10. ">Ray 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,993/47,869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.78 (95% CI 0.69 to 0.87)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0016" title="HuertaC , JohanssonS , WallanderMA , Garcia RodriguezLA . Risk factors and short‐term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine2007;167(9):935‐43. ">Huerta 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6,550/10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any statin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.70 (95% CI 0.50 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008203-bbs2-0010" title="DoggenCJ , LemaitreRN , SmithNL , HeckbertSR , PsatyBM . HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. Journal of Thrombosis and Haemostasis2004;2(5):700‐1. ">Doggen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465/1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simvastatin, pravastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simvastatin OR 0.51 (95% CI 0.29 to 0.91)</p> <p>Pravastatin OR 1.85 (95% CI 0.65 to 5.26)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval<br/> HERS: Heart and Estrogen/Progestin Replacement Study (HERS)<br/> HR: hazard ratio<br/> IRR: incidence rate ratio<br/> OR: odds ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Published studies reporting the frequency of venous thromboembolism (VTE) in statin users and nonusers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/full#CD008203-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008203-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All cases of VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Provoked VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Unprovoked VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All cases of VTE ‐ gender <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All cases of VTE ‐ age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Aged 70 ‐ 97 y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Aged 50 ‐ 69 y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Any MI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Fatal MI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Any stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Arterial revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Death after VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Confirmed death resulting from cardiovascular causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Any serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hepatic disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Myopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Rhabdomyolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Renal disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Muscular weakness, stiffness, or pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Gastrointestinal disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008203.pub3/references#CD008203-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008203.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008203-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008203-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008203-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008203-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pt#CD008203-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008203-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008203\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008203\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008203\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008203\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008203\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008203.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008203.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008203.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008203.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008203.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719002332"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008203.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719002336"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008203.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dde1ecc531be5',t:'MTc0MDcxOTAwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 